Mergers & Acquisitions - Rare diseases


Current filters:

Rare diseases

Popular Filters

26 to 32 of 32 results

Shire to acquire FerroKin BioSciences; drops Replagal BLA


Ireland-headquartered Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire privately-held…

FerroKin BioSciencesMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRare diseasesRegulationReplagalShire

Cushing’s syndrome patients to receive safer drug options


New upcoming treatments for Cushing’s syndrome promise to improve patient’s quality of life,…

Corcept TherapeuticsHRA PharmaKorlymMergers & AcquisitionsMifedrenNovartisPharmaceuticalRare diseasesResearchSignifor

Alexion to buy Enobia Pharma for potential $1 billion


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has reached agreement to acquire privately held Canadian…

Alexion Pharmaceuticalsasfotase alfaEnobia PharmaMergers & AcquisitionsPharmaceuticalRare diseases

ViroPharma buys option to acquire Meritage Pharma


ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

Actelion pulls out of Trophos option


Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

ViroPharma to acquire DuoCort Pharma for up to $164 million, adding European orphan drug to pipeline


The USA’s ViroPharma (Nasdaq: VPHM) says it has signed a definitive agreement to acquire DuoCort…

DuoCort PharmaMergers & AcquisitionsPharmaceuticalPlenadrenRare diseasesViroPharma

26 to 32 of 32 results

Back to top